Clinical trials: Non-Communicable Chronic Diseases
Hepatitis C, Chronic
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
This prospective, multicenter, observational cohort study will evaluate the efficacy and safety of pegylated interferon alfa (peginterferon alfa) (e.g.
- Trial name
- NCT01447446
- Testing
- Peg-IFN Alfa-2a, Peg-IFN Alfa-2b, Ribavirin
- Where
- 271 sites in Belgium, Egypt and 25 more
- Volunteers
- 4,442 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C, Chronic
Vaniprevir Plus PegIntron®/Ribavirin in Japanese Participants With Chronic Hepatitis C Who Are Non-responders to Previous Treatment (MK-7009-045)
The purpose of this study is to evaluate the safety, tolerability, and efficacy of vaniprevir (300 mg twice daily) given in combination with pegylated interferon alfa-2b (peg-IFN) and ribavirin (RBV) in Japanese participants with…
- Trial name
- NCT01405560
- Testing
- Vaniprevir, peg-IFN, ribavirin
- Volunteers
- 42 people
- Sponsor
- Merck Sharp & Dohme LLC
Carcinoma, Hepatocellular, Hepatitis C, Chronic
Digitalized Surveillance Management for Liver Cancer Risk Population in Improving Eearly Diagnosis Efficancy in Chinese Population (dSEARCH)
The goal of this study is to evaluate whether the standardized liver cancer risk stratification management can effectively improve the early diagnosis rate of liver cancer in the targeted risk population in China.
- Conditions
- Carcinoma, Hepatocellular, Hepatitis C, Chronic, Hepatitis B, Chronic, Cirrhosis, Liver
- Trial name
- dSEARCH (NCT05870969)
- Testing
- Liver cancer surveillance every 3 months, Liver cancer surveillance every 6 months, Liver cancer surveillance annually
- Where
- China
- Volunteers
- 20,000 people
- Sponsor
- Ruijin Hospital
Hepatitis C, Chronic
Hepatitis C Surveillance With Linkage to Care of Patients From Non-ID Departments in Jiangsu
Due to the occult nature of hepatitis C virus (HCV), it is estimated that less than 5% of people with chronic hepatitis C (CHC) infection knowing their status.
- Trial name
- NCT03772002
- Testing
- HCV screening
- Where
- 2 sites in China
- Volunteers
- 600 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Chronic Hepatitis C
A Study of Debio 025 in Combination With PegIFN Alpha-2a and Ribavirin in Chronic HCV Patients Non-responders to Standard Treatment
Debio 025 (alisporivir) is an oral cyclophilin inhibitor with a new mechanism of action demonstrating potent anti-hepatitis C virus (HCV) activity in pre-clinical models and patients.
- Trial name
- NCT00537407
- Testing
- Debio 025, Peg-IFNα2a, Ribavirin
- Where
- 7 sites in United States
- Volunteers
- 50 people
- Sponsor
- Debiopharm International SA
Chronic Hepatitis C
Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available Medications
The purpose of this study is to estimate the rate of sustained virologic response (SVR) SVR12, where SVR12 is defined as HCV RNA < LOQ (detectable or undetectable) 12 weeks post-treatment in Genotype 1 \& Genotype 4 treatment…
- Trial name
- NCT01455090
- Testing
- BMS-650032, BMS-790052, BMS-791325
- Where
- 32 sites in United States, France and 1 more
- Volunteers
- 320 people
- Sponsor
- Bristol-Myers Squibb
Non-Communicable Chronic Diseases, Survey and Questionnaire
Evaluation of Validity and Reliability of the Turkish Translation of the Digital Health Readiness Questionaire in Different Chronic Diseases
The World Health Organization (WHO) defines digital health as the field of knowledge and application related to any aspect of the adoption of digital technology in the stages of improvement.
- Conditions
- Non-Communicable Chronic Diseases, Survey and Questionnaire, Validation Studies, Digital Health
- Trial name
- NCT06581770
- Testing
- Survey using a questionnaire.
- Where
- Turkey (Türkiye)
- Volunteers
- 200 people
- Sponsor
- Istanbul Galata University
Hepatitis B, Chronic
Efficacy and Safety of Switching to Vemliver From Entecavir in Chronic Hepatitis B Patients Previously Treated With Entecavir
Enroll patients who are pre-treated with Entecavir at least 24 weeks and confirmed HBV antiviral (HBV DNA <69 IU/mL) effects. Subjects are given one test drug or comparator once a day for 48 weeks according to the results of…
- Trial name
- NCT06000657
- Testing
- Vemliver tablet, Baracross Tablet
- Where
- South Korea
- Volunteers
- 196 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Chronic Hepatitis b
Pegylated Interferon α in Previously Interferon-treated CHB（Leading Study）
Previous clinical practice and exploratory studies suggest that some patients who have not achieved functional cure in the first round of interferon therapy can achieve HBsAg clearance by interferon retreatment (intermittent…
- Trial name
- NCT06323681
- Testing
- Peginterferon α-2b based treatment group, NAs monotherapy group
- Where
- China
- Volunteers
- 2,016 people
- Sponsor
- Qing XIe
Chronic Hepatitis B Virus (HBV) Infection, Liver Fibrosis
Non-Invasive Model for Fibrosis Regression in HBV Patients
A total of 1000 chronic hepatitis B (CHB) patients with liver biopsy performed at least 1 year after antiviral therapy are retrospectively enrolled. All the patients received NAs treatment.
- Trial name
- NCT06874127
- Testing
- Nucleos(t)ide Analogs (NA)
- Where
- China
- Volunteers
- 1,100 people
- Sponsor
- Beijing Friendship Hospital
Ultra-Processed Food Consumption, Obesity Prevention
Sustainable and AI-Enabled Adolescents and Youth-Centred Interventions to Upgrade Food Choices and Promote Healthy, Sustainable Diets
This study aims to evaluate the effectiveness of an artificial intelligence (AI)-supported, context-aware digital nudging intervention designed to reduce ultra-processed food consumption and improve dietary sustainability among…
- Conditions
- Ultra-Processed Food Consumption, Obesity Prevention, Dietary Behaviour, Unhealthy Diet
- Trial name
- STAY-UP (NCT07514312)
- Testing
- Artificial intelligence-supported digital nudging
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Istanbul Gelisim University
HIV, Cardiovascular Disease
Ugandan Non-Communicable Diseases and Aging Cohort
Longitudinal cohort study of older-aged people living with HIV infection in southwestern Uganda and age and gender-matched HIV uninfected controls with the primary aim of measuring the epidemiology of cardiovascular and pulmonary…
- Conditions
- HIV, Cardiovascular Disease, Chronic Obstructive Pulmonary Disease, Atherosclerosis
- Trial name
- UGANDAC (NCT02445079)
- Testing
- This is an observational study only
- Where
- Uganda
- Volunteers
- 309 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Non-cirrhotic, Chronic Hepatitis B
TAF (Tenofovir Alafenamide) for Preventing Progression of Liver Disease in Non-cirrhotic Chronic HBV Infection With Normal ALT and Low Viral Load.
The main goal of therapy for patients with chronic HBV infection with no significant liver disease is to improve survival and quality of life by preventing disease progression, development of liver cirrhosis and consequently HCC…
- Trial name
- NCT05195450
- Testing
- Tenofovir alafenamide fumarate
- Where
- India
- Volunteers
- 200 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Hypertension, Diabetes
Developing a Learning Health System for Primary Care in Thailand
Research question: Can a Learning Health System (LHS) approach improve delivery of care and reduce inequalities in outcomes for people with hypertension and related non-communicable diseases (NCDs) compared to routine care in…
- Conditions
- Hypertension, Diabetes, Kidney Disease, Primary Care
- Trial name
- NCT06873243
- Testing
- Learning Health System Approach
- Where
- Thailand
- Volunteers
- 419 people
- Sponsor
- Queen Mary University of London
Chronic HBV Infection
A Study of EDP-514 in Patients With Chronic Hepatitis B Virus Infection Who Are Not Currently on Treatment
This is a randomized, double-blind, placebo-controlled study in viremic chronic hepatitis B subjects, assessing the safety, tolerability, pharmacokinetics and antiviral activity of 28 Days treatment with EDP-514.
- Trial name
- NCT04470388
- Testing
- EDP-514
- Where
- 10 sites in Hong Kong, Taiwan
- Volunteers
- 25 people
- Sponsor
- Enanta Pharmaceuticals, Inc
Hepatitis C, Chronic
The Effects of PegIntron Plus Rebetol in Subjects With Chronic Hepatitis C Not Responding to Pegasys (Study P03833)
This is an uncontrolled, non-randomized, open-label, multinational study designed to evaluate the efficacy and safety of PegIntron plus Rebetol in subjects with chronic hepatitis C.
- Trial name
- NCT00441584
- Testing
- PegIntron (peginterferon alfa-2b), Rebetol (ribavirin)
- Volunteers
- 117 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Hepatitis C
High-Dose Ribavirin and Peginterferon to Treat Chronic Hepatitis C Genotype 1
This study will evaluate the effectiveness of an experimental treatment regimen for hepatitis C (HCV). Standard treatment consists of combination therapy with ribavirin, taken by mouth twice a day, and Peginterferon, injected…
- Trial name
- NCT00735969
- Testing
- Peginterferon, Ribavirin
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Chronic Hepatitis C
Combined Ribavirin With Sofosbuvir/Velpatasvir/Voxilaprevir in Retreatment of Chronic Hepatitis C Non-responders
This study aims to assess the role of ribavirin as an adjuvant to sofosbuvir/velpatasvir/voxilaprevir combination in retreatment of chronic hepatitis C with previous treatment failure.
- Trial name
- NCT04695769
- Testing
- Sofosbuvir / Velpatasvir / Voxilaprevir Oral Tablet [Vosevi] plus Ribavirin, Sofosbuvir / Velpatasvir / Voxilaprevir Oral Tablet [Vosevi]
- Where
- Egypt
- Volunteers
- 281 people
- Sponsor
- Helwan University
HIV Seropositivity
Statins for Pulmonary and Cardiac Complications of Chronic HIV - Coordinating Center
Hypothesis: Statin therapy will decrease inflammation and slow progression of cardiopulmonary abnormalities in HIV.
- Trial name
- SPARC (NCT01881971)
- Testing
- Rouvastatin calcium
- Where
- 3 sites in United States
- Volunteers
- 23 people
- Sponsor
- Alison Morris
Chronic Hepatitis C, Obesity
Microarray Analysis of IFN-Induced Gene Expression in Obese and Non-Obese Patients With Chronic Hepatitis C
The response rate to interferon-based anti-viral therapy for chronic hepatitis C is lower in patients who are obese. However, it is not clear whether this is related to suboptimal dosing of the medication or alterated response in…
- Trial name
- NCT00322179
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Palo Alto Veterans Institute for Research